NDA 212269 · Chiesi
Ferriprox
Deferiprone · Oral · Iron Chelator
Accelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Mar 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 19, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
64
15 Phase 3, 4 recruiting
FAERS reports
3,286
2,205 serious, 381 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: AGRANULOCYTOSIS AND NEUTROPENIA • FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. [see Warnings and Precautions ( 5.1 )] • Measure the absolute neutrophil count (ANC) before starting FERRIPROX therapy and monitor regularly while on therapy. • Interrupt FERRIPROX therapy if neutropenia develops. [see Warnings and Precautions ( 5.1 )] • Interrupt FERRIPROX if infection develops, and monitor the ANC more frequently. [see Warnings and Precautions ( 5.1 )] • Advise patients taking FERRIPROX to report immediately any symptoms indicative of infection. [see Warnings and Precautions ( 5.1 )] WARNING: AGRANULOCYTOSIS AND NEUTROPENIA See full prescribing information for complete boxed warning. • FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may...
What it is approved for
From the label in effect Jan 28, 2026.
FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. ( 1 ) Limitation s of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.
Mechanism: Deferiprone is a chelating agent with an affinity for ferric ions (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable at physiological pH.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2021 Supplement 1 · Efficacy OrphanLabelLetter
- May 19, 2020 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalOrphanLabelLetterReview
1 products under this application
- FERRIPROX · DEFERIPRONE 1GM · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Deferiprone" as an intervention, any sponsor and status, largest first.
- Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00772928 · 1,167 participants · Start Oct 2003 · Primary completion May 2006
Drug: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®; Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® · For: Diphtheria; Tetanus; Haemophilus Infection and 2 more
Sites: Montgomery, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 23 sites in all
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Pivotal-lookingRecruiting
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06006091 · 858 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2026
Drug: Letrozole · For: Letrozole; Infertility, Female
Sites: Shanghai, China
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsPivotal-lookingCompleted
Consorzio per Valutazioni Biologiche e FarmacologicheAcademic, hospital or other
NCT01825512 · 435 participants · Start Mar 17, 2014 · Primary completion Sep 21, 2017
Drug: Deferiprone; Deferasirox · For: Chronic Iron Overload
Sites: Lushnje, Albania; Tirana, Albania; Nicosia, Cyprus · 22 sites in all
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseasePivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT02655315 · 372 participants · Start Feb 9, 2016 · Primary completion Sep 22, 2020
Drug: Deferiprone; Placebo · For: Parkinson Disease
Sites: Innsbruck, Austria; Prague, Czechia; Bordeaux, France · 25 sites in all
- Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT03293069 · 372 participants · Start Jan 30, 2019 · Primary completion Nov 11, 2023
Drug: Deferiprone; Placebo Oral Tablet · For: Amyotrophic Lateral Sclerosis
Sites: Angers, France; Brest, France; Bron, France · 15 sites in all
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171171 · 252 participants · Start May 2004 · Primary completion Nov 2006
Drug: deferasirox · For: Beta-Thalassemia; Hemosiderosis
Sites: Cairo, Egypt; Beirut, Lebanon; Muscat, Oman · 5 sites in all
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasPivotal-lookingTerminated
ApoPharmaIndustry
NCT02041299 · 230 participants · Start Apr 17, 2014 · Primary completion Apr 20, 2019
Drug: Deferiprone; Deferoxamine · For: Iron Overload; Sickle Cell Disease; Other Anemias
Sites: Oakland, California; Chicago, Illinois; New Orleans, Louisiana · 33 sites in all
- Efficacy Study of the Use of Sequential DFP-DFO Versus DFPPivotal-lookingCompleted
Azienda Ospedaliera V. CervelloAcademic, hospital or other
NCT00733811 · 213 participants · Start Sep 2000 · Primary completion Jan 2008
Drug: Deferiprone (DFP) and Deferoxamine (DFO); Deferiprone (DFP) · For: Beta-Thalassemia; Thalassemia Major
Sites: Palermo, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,187
- death238
- sickle cell anaemia with crisis218
- nausea178
- agranulocytosis163
- fatigue149
- ill-defined disorder147
- vomiting136
- neutropenia128
- pyrexia126
- prescribed overdose109
- diarrhoea103
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 8 |
| 2012 | 16 |
| 2013 | 113 |
| 2014 | 87 |
| 2015 | 192 |
| 2016 | 138 |
| 2017 | 92 |
| 2018 | 138 |
| 2019 | 117 |
| 2020 | 124 |
| 2021 | 267 |
| 2022 | 518 |
| 2023 | 349 |
| 2024 | 350 |
| 2025 | 375 |
| 2026 | 378 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ferriprox (Deferiprone)
2024 spending
$3.6M
Beneficiaries
39
267 claims
Per beneficiary
$91,169
$59.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $774,907 |
| 2022 | $3,753,026 |
| 2023 | $3,680,026 |
| 2024 | $3,555,600 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Deferiprone-associated myelotoxicity.
al-Refaie FN, Wonke B, Hoffbrand AV · Eur J Haematol 1994 · Case Reports, Clinical Trial
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.
Ayton S, Barton D, Brew B, et al. · JAMA Neurol 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Multicenter Study
- Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Zesiewicz TA, Wilmot G, Kuo SH, et al. · Neurology 2018 · Practice Guideline, Research Support, Non-U.S. Gov't
- Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.
Devos D, Rascol O, Meissner WG, et al. · J Parkinsons Dis 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial.
ElLaboudy MA, Saber MM, Adly AA, et al. · Clin Nutr 2025 · Randomized Controlled Trial
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.